Propylene Glycol
drug drugOn this page
Also known as E-1520E1520E490FEMA NO. 2940Ins no.1520Ins-1520Isopropylene glycolKilfrost abc-sKollisolv pgMethyl glycolNSC-69860Propylene glycol (solvent)Propylene glycol dl-formPropyleneglycolumSID17389749SID49816670SID144209010SID144210326SID144211758
Summary
Propylene Glycol (CHEMBL286398) is an approved small molecule; indicated across 3 conditions including dry eye syndrome and heavy metal poisoning.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 13
- Chemistry: 76.09 Da · C3H8O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL286398 |
| Name | Propylene Glycol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 1030 |
| ChEBI | CHEBI:16997 |
| Molecular formula | C3H8O2 |
| Molecular weight | 76.09 |
| InChIKey | DNIAPMSPPWPWGF-UHFFFAOYSA-N |
SMILES: CC(CO)O
IUPAC name: propane-1,2-diol
ChEBI definition: The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (−59°C) and high-boiling (188°C) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.
Pharmacological roles (ChEBI): allergen.
Other ChEBI roles (chemical / environmental): protic solvent, human xenobiotic metabolite, mouse metabolite.
Also known as: E-1520, E1520, E490, FEMA NO. 2940, Ins no.1520, Ins-1520, Isopropylene glycol, Kilfrost abc-s, Kollisolv pg, Methyl glycol, NSC-69860, Propylene glycol
Patent coverage: 540,819 distinct patent families (1,525,139 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| TDP1 | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_3931240 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| dry eye syndrome | 3 | MONDO:0006733 | EFO:1000906 |
| heavy metal poisoning | 2 | MONDO:0023305 | EFO:1001518 |
| constipation disorder | 2 | MONDO:0002203 | HP:0002019 |
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE4 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07451184 | PHASE4 | RECRUITING | Comparison of Ocular Lubricants in People With Symptoms of Dry Eye |
| NCT00493662 | PHASE4 | COMPLETED | Cross-Over Evaluation of Two Lubricating Eye Drops |
| NCT05116306 | PHASE3 | UNKNOWN | Clinical and Radiographic Evaluation of Hyaluronic Acid Compared to Propylene Glycol as Vehicle for Double Antibiotic Paste in Lesion Sterilization and Tissue Repair Technique for Non-Vital Primary Molars |
| NCT03066817 | PHASE1/PHASE2 | SUSPENDED | Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients |
| NCT04380090 | PHASE2 | COMPLETED | Post-Operative Constipation Following Total Knee Arthroplasty |
| NCT01718028 | Not specified | COMPLETED | The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects |
| NCT01967147 | Not specified | COMPLETED | Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects |
| NCT02380248 | Not specified | COMPLETED | Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects |
| NCT02511379 | Not specified | TERMINATED | Clinical Evaluation of Systane® Balance in Dry Eye Subjects |
| NCT02585791 | Not specified | TERMINATED | Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette(NCFE) Vapors |
| NCT02776670 | Not specified | COMPLETED | Clinical Outcomes Following Treatment With SYSTANE® BALANCE |
| NCT03404011 | Not specified | COMPLETED | Acute Effects of Propylene Glycol/Glycerol Intake on Blood Parameters |
| NCT03474146 | Not specified | COMPLETED | Comparative Evaluation of Antiplaque and Antigingivitis Efficacy of Ocimum Sanctum (Tulsi) Extract |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: dry eye syndrome, heavy metal poisoning, constipation disorder